Skip Navigation


Annals of Oncology Advance Access originally published online on May 3, 2006
Annals of Oncology 2006 17(6):909-913; doi:10.1093/annonc/mdl049
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/6/909    most recent
mdl049v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Liedtke, M.
Right arrow Articles by Zelenetz, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liedtke, M.
Right arrow Articles by Zelenetz, A. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population

M. Liedtke{dagger}, P. A. Hamlin, C. H. Moskowitz and A. D. Zelenetz*

Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, USA

* Correspondence to: Dr A. D. Zelenetz, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Tel: +1 212–639–2656; Fax: +1 212–717–3036; E-mail: a-zelenetz{at}ski.mskcc.org

Background: Approximately one-third of the patients with relapsed aggressive non-Hodgkin's lymphoma (NHL) are cured by second-line chemotherapy followed by high-dose consolidation. The age-adjusted international prognostic index determined at the time of relapse (sAAIPI) predicts outcome in relapsed diffuse large B-cell lymphoma, suggesting that the success of salvage therapy could be enhanced by early relapse detection. This study evaluated the role of surveillance imaging in detection of relapsed disease and its impact on outcome of salvage treatment.

Patients and methods: One hundred and eight patients with relapsed aggressive NHL were treated with ICE-based second-line chemotherapy. Relapses were categorized as detected by imaging, examination, or patient-reported symptoms.

Results: Twenty per cent of relapses were detected by routine imaging while 80% were identified by reported symptoms or abnormalities on exam. Patients were 4.1 times (95% CI: 1.7–10.2) more likely to have low risk disease if relapse was diagnosed by routine imaging (group 1) compared with those diagnosed by reported symptoms or physical findings (group 2). Median overall 5-year survival for group 1 versus group 2 was 54% and 43% respectively (P = 0.13).

Conclusion: These results suggest that routine surveillance imaging can identify a population of patients with a more favorable outcome based on the sAAIPI.

Key words: lymphoma, relapse, surveillance imaging, follow-up


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
B. Cheson
The Case Against Heavy PETing
J. Clin. Oncol., April 10, 2009; 27(11): 1742 - 1743.
[Full Text] [PDF]

Home page
 BloodHome page
P. Seam, M. E. Juweid, and B. D. Cheson
The role of FDG-PET scans in patients with lymphoma
Blood, November 15, 2007; 110(10): 3507 - 3516.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. O. Armitage
How I treat patients with diffuse large B-cell lymphoma
Blood, July 1, 2007; 110(1): 29 - 36.
[Full Text] [PDF]

Home page
 JCOHome page
B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al.
Revised Response Criteria for Malignant Lymphoma
J. Clin. Oncol., February 10, 2007; 25(5): 579 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. O. Armitage and F. R. Loberiza
Is there a place for routine imaging for patients in complete remission from aggressive lymphoma?
Ann. Onc., June 1, 2006; 17(6): 883 - 884.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.